Collective Action Planned for April 21,
Strike Set to Begin on May 1

Samsung Biologics is facing its first strike crisis since its establishment in 2011.


According to the Samsung Biologics Win-Win Labor Union on March 30, 95.52% of union members who responded to the strike vote held until the previous afternoon voted in favor. The overall voter turnout was 95.38%, with 3,508 votes cast. The labor and management sides at Samsung Biologics have failed to reach an agreement after 13 rounds of wage and collective bargaining negotiations. As a result, the union halted the mediation process on March 23 and began the voting procedure on March 24.

Samsung Biologics Faces First-Ever Strike Crisis... Last-Minute Tug-of-War Expected in Labor-Management Talks View original image

The main issues are wages and bonuses. The union is demanding a 14% increase in base salary and the payment of 20% of operating profit as excess performance bonuses (OPI). It is also reportedly requesting a KRW 30 million incentive per employee and an allocation of company shares over three years. The management has offered a total wage increase of 6.2%, an incentive payment equal to 200% of the base salary, and expanded shift allowances. Regarding OPI, the company is sticking to the group guideline of either 10% of operating profit or 20% based on economic value added (EVA).


Demands related to personnel and management rights have also been raised. The union insists that all personnel matters—including recruitment, promotion, disciplinary action, awards, and reassignment—require prior consultation with the union. They also assert that any management decisions related to division, merger, or transfer of business rights will not be recognized as valid without labor-management agreement. The union plans to hold informal negotiations once CEO John Rim returns to Korea. If an agreement is not reached, they intend to begin collective action on April 21, followed by a strike starting May 1. The Samsung Biologics union has 3,689 members, accounting for about 75% of all employees.


There are concerns that a strike by the Samsung Biologics union could deal a blow to the company’s global business competitiveness. Samsung Biologics has grown by leveraging strict quality control and adherence to delivery schedules, so production disruptions caused by a strike would be especially damaging. If the strike becomes a reality and plant operations—which must run 24/7—are halted or production schedules are disrupted, the company could lose clients and suffer damage to its external credibility. Since bioprocessing involves producing pharmaceutical raw materials using microorganisms or animal cells, equipment cannot be stopped midway through the process. The sequence from cell culture to purification typically takes several weeks, and during this period, optimal conditions for cell survival—such as temperature, humidity, and oxygen concentration—must be continuously and precisely maintained.


The biopharmaceutical CDMO (Contract Development and Manufacturing Organization) industry is being fostered as a strategic sector in many countries, and competition is intensifying. Samsung Biologics currently has the world’s largest production capacity at 785,000 liters, but rivals such as Lonza, Japan’s Fujifilm, and China’s WuXi Biologics and CL Biologics are rapidly expanding through multi-trillion-won investments.



Since both labor and management recognize the potential damage a full-scale strike could cause, it is widely expected that both sides will pour their efforts into a last-minute tug-of-war for a dramatic resolution during the informal negotiations to be held after CEO John Rim’s return. The union stated, "The strike itself is not the goal," adding, "If management brings forward an improved proposal during the remaining period, we are willing to engage in talks at any time." A management representative also commented, "We will continue to work toward a smooth conclusion to the wage negotiations." Reported by Jeong Donghun and Lee Sungmin.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing